Results 21 to 30 of about 101 (70)

Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics

Chemistry – A European Journal, Volume 32, Issue 37, 1 October 2026.
A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kristina A. Kostadinova, Jan L. Venne, Sona Krajcovicova, James Dodgson, Wouter F. J. Hogendorf, Thomas E. Nielsen, David Hymel, Hannah Bolt, Andie Collinson, Jason Day, Jefferson Revell, David R. Spring   +11 more
wiley   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future

Medicinal Research Reviews, Volume 45, Issue 1, Page 29-65, January 2025.
Abstract Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) are incretin‐based agents that lower both blood sugar levels and promote weight loss. They do so by activating pancreatic GLP‐1 receptors (GLP‐1R) to promote glucose‐dependent insulin release and inhibit glucagon secretion ...
James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, Richard Le, Christina A. Bursill, Chinmay S. Marathe, Adam J. Nelson, Peter J. Psaltis   +7 more
wiley   +1 more source

Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives. [PDF]

Front Endocrinol (Lausanne)
Mehetre KN, Dawane JS.
europepmc   +1 more source

Future Directions in the Medical Treatment of Obesity: A Narrative Review. [PDF]

Adv Ther
Bassatne A, Rizo I.
europepmc   +1 more source

Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide. [PDF]

J Midlife Health
Agrawal PK, Garg R.
europepmc   +1 more source

GLP-1-Based Therapy for Obstructive Sleep Apnoea. [PDF]

Respirology
Zheng Y, Yee BJ.
europepmc   +1 more source

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. [PDF]

BMJ Med
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y.   +13 more
europepmc   +1 more source

For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better? [PDF]

Biology (Basel)
Giang C, Meng J, Mohammad MA, Liu Z, Wu X, Zhu Y.   +5 more
europepmc   +1 more source

Amycretin in the Treatment of Obesity: Hormonal Mechanisms, Clinical Evidence, and Therapeutic Perspectives of the New Generation of Incretin Agonists

Jaimiro Azevedo de Aquino Filho, Carolina Fátima Gioia Nava, Fernanda Laignier Gonçalves, Osni Vieira de Barros, Hellem Victória da Penha Souza, Anna Gabriela Pereira Ferreira, Digilany Aparecida de Souza Lemes, Rafael Ribeiro Ramos, Jordana Avancini Fernandes Moura, Nathália Gomes de Morais, Glenda Ferreira Ribeiro Bueno, Ana Clara Vilela Leal, Letícia Oliveira de Souza   +12 more
core   +1 more source